{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:31:43Z","timestamp":1791873103718,"version":"4.3.4"},"reference-count":46,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma phosphorylated\u2010tau at threonine\u2010217 (p\u2010tau217) and threonine\u2010181 (p\u2010tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co\u2010pathology may contribute to its clinical heterogeneity. However, the existing literature has predominantly focused on p\u2010tau181, with comparatively limited investigation of p\u2010tau217.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim is to evaluate plasma p\u2010tau217 and p\u2010tau181 as biomarkers of AD co\u2010pathology across the PD cognitive spectrum, relative to a cohort of dementia\u2010free older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma p\u2010tau217 and p\u2010tau181 were measured in 70 PD patients and 83 older adults. Associations with cognitive impairment, disease severity (Hoehn\u2010and\u2010Yahr), and neurostructural measures\u2014including global atrophy, hippocampal volume, and a magnetic resonance imaging\u2010based AD signature\u2014were assessed using correlation and dominance analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both p\u2010tau217 and 181 were higher in PD with cognitive impairment and dementia compared with cognitively normal PD. P\u2010tau217 showed stronger associations than p\u2010tau181 with AD\u2010like neurostructural changes, multidomain cognitive deficits, greater disease severity, and reduced functional independence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Plasma p\u2010tau217 and p\u2010tau181 may serve as scalable markers of AD\u2010related processes associated with neurostructural, clinical, and cognitive outcomes in PD. \u00a9 2026 The Author(s).\n                      <jats:italic>Movement Disorders<\/jats:italic>\n                      published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.70392","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:47:48Z","timestamp":1781588868000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma p\u2010tau217 Versus p\u2010tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease\u2010Related Neurostructural Changes and Cognitive Function"],"prefix":"10.1002","author":[{"given":"Eleonora","family":"Fiorenzato","sequence":"first","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cauzzo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Musso","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"},{"name":"Laboratory Medicine, University\u2010Hospital of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[{"name":"Department of General Psychology University of Padua  Padua Italy"},{"name":"IRCCS San Camillo Hospital  Venice Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ceolin","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"},{"name":"Department of Neurobiology Care Sciences and Society, Karolinska Institutet and Stockholm, University, Aging Research Center  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cosma","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo Alessandro","family":"Fogliano","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service de Neurologie des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, IMNc, Place Am\u00e9lie Raba\u2010L\u00e9on  Bordeaux France"},{"name":"University de Bordeaux, CNRS, IMN, UMR  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Misenti","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Moz","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"},{"name":"Laboratory Medicine, University\u2010Hospital of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Nasi","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vianello","sequence":"additional","affiliation":[{"name":"Complex Operative Unit (UOC) of the Psychology, Neurology Hospital division, Padua University Hospital  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-3971","authenticated-orcid":false,"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, DIMED, University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"},{"name":"Laboratory Medicine, University\u2010Hospital of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sergi","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013DIMED University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience Padua Neuroscience Center (PNC), University of Padua  Padua Italy"},{"name":"IRCCS San Camillo Hospital  Venice Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the OPA Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies","volume":"90","author":"Smith C","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin DJ","year":"2012","journal-title":"Ann Neurol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mds.29295","article-title":"Effect of amyloid on cognitive performance in Parkinson's disease and dementia with Lewy bodies","volume":"38","author":"Baik K","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","article-title":"The contribution of beta\u2010amyloid to dementia in Lewy body diseases: a 1\u2010year follow\u2010up study","volume":"3","author":"Biundo R","year":"2021","journal-title":"Brain Commun"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123617","article-title":"The role of blood\u2010based biomarkers in parkinsonian disorders, Alzheimer's disease and frontotemporal dementia","volume":"476","author":"Campagnolo M","year":"2025","journal-title":"J Neurol Sci"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-022-00384-x","article-title":"Plasma p\u2010tau181, neurofilament light chain and association with cognition in Parkinson's disease","volume":"8","author":"Batzu L","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ana.27003","article-title":"Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy body disease","volume":"96","author":"Abdelnour C","year":"2024","journal-title":"Ann Neurol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/NRR.NRR-D-24-00592","article-title":"Potential biofluid markers for cognitive impairment in Parkinson's disease","volume":"21","author":"Chen J","year":"2026","journal-title":"Neural Regen Res"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/gerona\/glad189","article-title":"Evolution and predictive role of plasma Alzheimer's disease\u2010related pathological biomarkers in Parkinson's disease","volume":"78","author":"Lin J","year":"2023","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/mds.30238","article-title":"Plasma phosphorylated Tau181 as a biomarker for Alzheimer's disease Co\u2010pathology in Lewy body disease","volume":"40","author":"Ye R","year":"2025","journal-title":"Mov Disord"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jnc.15601","article-title":"Plasma \u03b1\u2010synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease","volume":"161","author":"Ren J","year":"2022","journal-title":"J Neurochem"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/brain\/awae346","article-title":"A comprehensive head\u2010to\u2010head comparison of key plasma phosphorylated tau 217 biomarker tests","volume":"148","author":"Warmenhoven N","year":"2025","journal-title":"Brain"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho\u2010tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist S","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2025.3217","article-title":"Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease","volume":"82","author":"Salvad\u00f3 G","year":"2025","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head\u2010to\u2010head comparison of 10 plasma phospho\u2010tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze S","year":"2023","journal-title":"Brain"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head\u2010to\u2010head comparison of leading blood tests for Alzheimer's disease pathology","volume":"20","author":"Schindler SE","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack CR","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-026-04206-y","article-title":"Predicting onset of symptomatic Alzheimer's disease with plasma p\u2010tau217 clocks","volume":"32","author":"Petersen KK","year":"2026","journal-title":"Nat Med"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton NJ","year":"2024","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p\u2010tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson\u2010Carlgren N","year":"2020","journal-title":"Brain"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour A","year":"2024","journal-title":"EBioMedicine"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70274","article-title":"Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes","volume":"21","author":"Hannaway N","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma Phospho\u2010tau identifies Alzheimer's Co\u2010pathology in patients with Lewy body disease","volume":"36","author":"Hall S","year":"2021","journal-title":"Mov Disord"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1638852","article-title":"Detecting amyloid and tau pathology in Parkinson's disease, 4R\u2010tauopathies and control subjects with plasma pTau217","volume":"16","author":"Musso G","year":"2025","journal-title":"Front Neurol"},{"issue":"6","key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/ana.78201","article-title":"Association between plasma P\u2010tau217 and Alzheimer's Copathology and cognitive decline in Parkinson's disease","volume":"99","author":"Tropea TF","year":"2026","journal-title":"Ann Neurol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mds.29678","article-title":"Brain dynamics complexity as a signature of cognitive decline in Parkinson's disease","volume":"39","author":"Fiorenzato E","year":"2024","journal-title":"Mov Disord"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson's disease: updated systematic review and proposals","volume":"38","author":"Jost ST","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123283","article-title":"Optimal MMSE and MoCA cutoffs for cognitive diagnoses in Parkinson's disease: a data\u2010driven decision tree model","volume":"466","author":"Fiorenzato E","year":"2024","journal-title":"J Neurol Sci"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jgs.12742","article-title":"Montreal cognitive assessment memory index score (MoCA\u2010MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease","volume":"62","author":"Julayanont P","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00702-024-02746-6","article-title":"Validation of the Italian version of the Parkinson's disease\u2010 cognitive functional rating scale","volume":"131","author":"Garon M","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"key":"e_1_2_9_32_1","article-title":"Diagnostic performances and cut\u2010off verification of blood pTau 217 on the Lumipulse platform for amyloid deposition in Alzheimer's disease","volume":"63","author":"Musso G","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000442443","article-title":"Measuring global brain atrophy with the brain volume\/cerebrospinal fluid index: normative values, cut\u2010offs and clinical associations","volume":"16","author":"Orellana C","year":"2016","journal-title":"Neurodegener Dis"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.576029","article-title":"Machine learning for diagnosis of AD and prediction of MCI progression from brain MRI using brain anatomical analysis using diffeomorphic deformation","volume":"11","author":"Syaifullah AH","year":"2021","journal-title":"Front Neurol"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1037\/1082-989X.8.2.129","article-title":"The dominance analysis approach for comparing predictors in multiple regression","volume":"8","author":"Azen R","year":"2003","journal-title":"Psychol Methods"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/mds.29564","article-title":"Basal forebrain atrophy, cortical thinning, and amyloid\u2010\u03b2 status in Parkinson's disease\u2010related cognitive decline","volume":"38","author":"Labrador\u2010Espinosa MA","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.760518","article-title":"Quantification of brain \u03b2\u2010amyloid load in Parkinson's disease with mild cognitive impairment: a PET\/MRI study","volume":"12","author":"Garon M","year":"2021","journal-title":"Front Neurol"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41531-024-00745-8","article-title":"Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease","volume":"10","author":"Hiraga K","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"e_1_2_9_39_1","volume-title":"Longitudinal Analysis of Plasma Biomarkers for Freezing of Gait in Parkinson's Disease","author":"Ou R","year":"2022"},{"key":"e_1_2_9_40_1","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12856-6","article-title":"Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8\u2010year longitudinal study","volume":"272","author":"Xu F","year":"2024","journal-title":"J Neurol"},{"key":"e_1_2_9_41_1","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s10072-025-08421-2","article-title":"Converging pathologies in neurodegeneration: the mechanistic interplay between \u03b1\u2010Synuclein and tau in Alzheimer's and Parkinson's","volume":"46","author":"Jeyabalan JB","year":"2025","journal-title":"Neurol Sci"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/brain\/awad388","article-title":"Nigrostriatal tau pathology in parkinsonism and Parkinson's disease","volume":"147","author":"Chu Y","year":"2024","journal-title":"Brain"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fneur.2019.00391","article-title":"Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease","volume":"10","author":"Melzer TR","year":"2019","journal-title":"Front Neurol Frontiers"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.25811","article-title":"Evolution of Alzheimer's disease cerebrospinal fluid biomarkers in early Parkinson's disease","volume":"88","author":"Irwin DJ","year":"2020","journal-title":"Ann Neurol"},{"key":"e_1_2_9_45_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical Spectrum","volume":"79","author":"Jansen WJ","year":"2022","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_46_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","article-title":"Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia","volume":"80","author":"Gomperts SN","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1093\/brain\/awaf033","article-title":"Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum","volume":"148","author":"Fern\u00e1ndez Arias J","year":"2025","journal-title":"Brain"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.70392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:47:54Z","timestamp":1781588874000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.70392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":46,"alternative-id":["10.1002\/mds.70392"],"URL":"https:\/\/doi.org\/10.1002\/mds.70392","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mds.70392"}}